Abstract
Clinical trials often report surrogate endpoint data. A surrogate endpoint is a biological marker or clinical sign that can be substituted for a patient-important outcome. Using surrogate endpoints correctly may facilitate and expedite clinical trials and may improve medical decisions. However, rigorous criteria must be met for an endpoint to be considered a valid surrogate. The purpose of this article is to review the topic of surrogate endpoints in the context of a urologic encounter.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 447-453 |
| Number of pages | 7 |
| Journal | Urologic Oncology: Seminars and Original Investigations |
| Volume | 29 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2011 |
Keywords
- Biological Markers
- Data Interpretation
- Evidence-based medicine
- Surrogate endpoints
ASJC Scopus subject areas
- Oncology
- Urology
Fingerprint
Dive into the research topics of 'Advanced topics in evidence-based urologic oncology: Surrogate endpoints'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS